RNAZ
Transcode Therapeutics, Inc.
Key Financials
Operating Income
$-15660697
↑ 19.4%
Total Liabilities
$9.3M
↑ 163.9%
Total Assets
$7.3M
↑ 41.1%
Shareholders' Equity
$-2018734.00
↓ 223.0%
Cash & Equivalents
$5.8M
↑ 110.0%
EPS (Diluted)
$-47.14
↑ 54.5%
Net Income
$-16754971
↑ 9.7%
Operating Cash Flow
$-13335947.00
↑ 26.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RNAZ |
| Company Name | Transcode Therapeutics, Inc. |
| CIK | 1829635 |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-301-6857 |